IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by LRI Investments LLC

LRI Investments LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 129 shares of the company’s stock after purchasing an additional 23 shares during the quarter. LRI Investments LLC’s holdings in IDEXX Laboratories were worth $63,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Riverview Trust Co acquired a new stake in IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the first quarter valued at $26,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $28,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth about $33,000. Finally, Private Wealth Management Group LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $34,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.7 %

Shares of IDXX traded down $3.60 during mid-day trading on Friday, reaching $488.13. The company’s stock had a trading volume of 255,571 shares, compared to its average volume of 486,760. The stock has a market cap of $40.31 billion, a PE ratio of 47.25, a price-to-earnings-growth ratio of 3.91 and a beta of 1.32. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The company’s 50 day moving average is $483.31 and its 200 day moving average is $510.24.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the business posted $2.67 EPS. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IDXX shares. Barclays reduced their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Morgan Stanley decreased their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.